181 related articles for article (PubMed ID: 16619445)
1. "Racially-tailored" medicine unraveled.
Hoffman S
Am Univ Law Rev; 2005 Dec; 55(2):395-452. PubMed ID: 16619445
[No Abstract] [Full Text] [Related]
2. Ethnic pharmacology: science, research, race, and market share.
O'Malley P
Clin Nurse Spec; 2005; 19(6):291-3. PubMed ID: 16294053
[No Abstract] [Full Text] [Related]
3. Medicine. Race and reification in science.
Duster T
Science; 2005 Feb; 307(5712):1050-1. PubMed ID: 15718453
[No Abstract] [Full Text] [Related]
4. Pharmacogenetics and ethnically targeted therapies: racial drugs need to be put in context.
Kahn JD
BMJ; 2005 Jun; 330(7506):1508; author reply 1508. PubMed ID: 15976430
[No Abstract] [Full Text] [Related]
5. The use of race and ethnicity in medicine: lessons from the African-American Heart Failure Trial.
Cohn JN
J Law Med Ethics; 2006; 34(3):552-4, 480. PubMed ID: 17144178
[TBL] [Abstract][Full Text] [Related]
6. Genotyping the future: scientists' expectations about race/ ethnicity after BiDil.
Tutton R; Smart A; Martin PA; Ashcroft R; Ellison GT
J Law Med Ethics; 2008; 36(3):464-70. PubMed ID: 18840237
[TBL] [Abstract][Full Text] [Related]
7. U.S. to review drug intended for one race.
Saul S
N Y Times Web; 2005 Jun; ():A1, A15. PubMed ID: 15966118
[No Abstract] [Full Text] [Related]
8. "Ethnic drugs".
Kahn J
Hastings Cent Rep; 2005; 35(1):1 p following 48. PubMed ID: 15799501
[No Abstract] [Full Text] [Related]
9. Immigrants' rights to health care.
Drake SB
Clgh Rev; 1986; 20(4):498-510. PubMed ID: 11659094
[No Abstract] [Full Text] [Related]
10. The isosorbide-hydralazine story: is there a case for race-based cardiovascular medicine?
Ferdinand KC
J Clin Hypertens (Greenwich); 2006 Mar; 8(3):156-8. PubMed ID: 16522991
[No Abstract] [Full Text] [Related]
11. BiDil for heart failure in black patients.
Kahn JD
Ann Intern Med; 2007 Aug; 147(3):215; author reply 215-6. PubMed ID: 17679713
[No Abstract] [Full Text] [Related]
12. BiDil for heart failure in black patients.
Bibbins-Domingo K; Fernandez A
Ann Intern Med; 2007 Aug; 147(3):214-5; author reply 215-6. PubMed ID: 17679712
[No Abstract] [Full Text] [Related]
13. The case of BiDil: a policy commentary on race and genetics.
Carlson RJ
Health Aff (Millwood); 2005; Suppl Web Exclusives():W5-464-8. PubMed ID: 16219648
[TBL] [Abstract][Full Text] [Related]
14. BiDil for heart failure in black patients: The U.S. Food and Drug Administration perspective.
Temple R; Stockbridge NL
Ann Intern Med; 2007 Jan; 146(1):57-62. PubMed ID: 17200223
[TBL] [Abstract][Full Text] [Related]
15. Question: does isosorbide dinitrate/hydralazine therapy benefit systolic heart failure patients with renal insufficiency?
Pan L; Payne J; Clark M
J Okla State Med Assoc; 2011 Feb; 104(2):49-50. PubMed ID: 21815321
[No Abstract] [Full Text] [Related]
16. The sex-bias myth in medicine.
Kadar AG
Atl Mon; 1994 Aug; 274(2):66-70. PubMed ID: 11659876
[No Abstract] [Full Text] [Related]
17. How a drug becomes "ethnic": law, commerce, and the production of racial categories in medicine.
Kahn J
Yale J Health Policy Law Ethics; 2004; 4(1):1-46. PubMed ID: 15052858
[No Abstract] [Full Text] [Related]
18. Hydralazine and nitrates: beyond race and ethnicity.
Ghali JK
J Card Fail; 2007 Apr; 13(3):238. PubMed ID: 17448423
[No Abstract] [Full Text] [Related]
19. Drugs tailored to race move a step closer to reality.
Senior K
Drug Discov Today; 2005 Aug; 10(16):1076-7. PubMed ID: 16182189
[No Abstract] [Full Text] [Related]
20. Popular representations of race: the news coverage of BiDil.
Caulfield T; Harry S
J Law Med Ethics; 2008; 36(3):485-90. PubMed ID: 18840240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
